Astellas, Daiichi Move Ahead With Factor Xa Programs
This article was originally published in PharmAsia News
Executive Summary
Astellas and Daiichi Sankyo both are on track to proceed to Phase III for their respective oral Factor Xa inhibitors, the companies indicated in second quarter earnings presentations on Nov. 7